Steris

Current directors and officers who also hold a role at another S&P 500 company.

• Christopher S. HollandJBL · Director
• Louis ShapiroZBH · Director
• Mohsen SohiBKR · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Aug 6, 2026

   The Original Form 8-K reported that the Board of Directors of the Company (the “Board”) increased its size from nine to ten members on May 5, 2026, and elected Pierre Boulud to serve as a Director effective as of that date. In accordance with the Instructions to

   Read the 8-K filing
2. May 7, 2026

   On May 1, 2026, Richard C. Breeden notified STERIS plc (the “Company”) that he will not stand for reelection to the Board of Directors (the “Board”) at the Company’s 2026 Annual General Meeting of Shareholders. Mr. Breeden’s decision to retire is not the result of any disagreement with the Company on any matters related to the Company’s operations, policies or practices. The Company and the Board thank Mr. Breeden for his 18 years of service to the Company as a Director. On May 5, 2026, the Board of the Company increased its size from nine to ten members and appointed Pierre Boulud to serve as a director effective as of that date. Mr. Boulud, age 54, is the Chief Executive Officer of bioMérieux, a biotechnology company focused on in vitro diagnostics, having served in that role since June 2023. Mr.

   Read the 8-K filing
3. Apr 6, 2026

   On March 31, 2026, STERIS plc (the “Company”) and Michael J. Tokich, the Company’s former Chief Financial Officer, entered into an amendment (the “Amendment”) to the Transition Agreement, dated August 5, 2025, between the Company and Mr. Tokich (the “Agreement”). In general, the Agreement governs the compensation and benefits that Mr. Tokich receives for his post-executive employment with the Company. Pursuant to the Amendment, Mr. Tokich’s employment with the Company as a senior financial advisor will be extended on a part-time basis from April 1, 2026 through March 31, 2027 (the “Extended Advisor Period”). The Amendment also provides that, during the Extended Advisor Period, Mr. Tokich’s annual base salary will be reduced to $60,000, Mr.

   Read the 8-K filing
4. Aug 6, 2025

   Resignation of Chief Financial Officer On July 31, 2025, Michael J. Tokich notified the Board of Directors (the “Board”) of his resignation from his current role as Senior Vice President and Chief Financial Officer of the Company. Mr. Tokich and the Company have entered into a Transition Agreement, dated August 5, 2025 (the “Transition Agreement”). The Transition Agreement will take effect on August 18, 2025. The Transition Agreement provides for a continuation of Mr. Tokich’s employment with the Company as a senior financial advisor until March 31, 2026 (the “Senior Advisor Period”), subject to potential termination by the Company for “Cause” or because of Mr. Tokich’s death or “Disability” (“Cause” and “Disability” used as defined in the Transition Agreement), by the Company after January 1, 2026 for any reason or by Mr. Tokich at any time for any reason.

   Read the 8-K filing
5. Jul 3, 2025

   On July 1, 2025, Dr. Richard Steeves notified STERIS plc (the “Company”) that he will retire from the Board of Directors (the “Board”) on the date of the Company’s Annual General Meeting of Shareholders (the “Annual Meeting”) to be held on July 31, 2025. Therefore, Dr. Steeves will not stand for re-election to the Board at the Annual Meeting. Dr. Steeves’ decision to retire is not the result of any disagreement with the Company on any matters related to the Company’s strategy, operations, policies or practices. The Company and the Board thank Dr. Steeves for his 10 years of service to the Company as a Director.

   Read the 8-K filing
6. Jul 27, 2023

   , among others. The Original Form 8-K reported that the Board of Directors of the Company (the “Board”) increased its size from nine to ten on May 3, 2023, and elected Dr. Esther Alegria to serve as a Director effective as of that date. In accordance with the Instructions to

   Read the 8-K filing
7. May 3, 2023

   The Board of Directors (the “Board”) of STERIS plc (the “Company”) increased its size from nine to ten members on May 3, 2023, and elected Dr. Esther Alegria to serve as a director effective as of that date. Dr. Alegria, age 64, has been the Founder and Chief Executive Officer of APIE Therapeutics, a preclinical stage pharmaceutical company, since 2020. From 2016 to 2020, Dr. Alegria served as the President and Senior Executive Advisor at Catalyst Excel & Advance, an advisory firm providing operational guidance to senior executives working to launch new pharmaceutical and biopharmaceutical companies. From 2005 to 2015, Dr. Alegria held positions of increasing responsibility at Biogen, Inc., most recently as Senior Vice President, Global Manufacturing. Since 2021, Dr.

   Read the 8-K filing
8. Aug 2, 2021

   , among others. The Original Form 8-K reported that the Board of Directors of the Company (the “Board”) increased its size from ten to eleven on May 5, 2021, and appointed Paul E. Martin to serve as a Director effective as of that date. In accordance with the Instructions to

   Read the 8-K filing
9. May 11, 2021

   The Board of Directors (the “Board”) of STERIS plc (the “Company”) increased its size from ten to eleven members on May 5, 2021, and appointed Paul E. Martin to serve as Director effective as of that date. Mr. Martin, age 63, most recently served as the Senior Vice President and Chief Information Officer of Baxter International, from January 1, 2011 to October 2020. He is a member of the Board of Directors of Unisys Corporation, Ping Identity Holding Corp. and Owens Corning, a member of the Audit and Finance Committee of Unisys Corporation and chair of its Security and Risk Committee, a member of the Audit and Finance Committees of Owens Corning, and a member of the Audit Committee of Ping Identity. Mr.

   Read the 8-K filing
10. Feb 3, 2021

    Walter M Rosebrough On January 29, 2021, Walter M Rosebrough advised the Board of Directors (the “Board”) of STERIS plc (the “Company”) of his intention to retire as President and CEO of the Company at the Company’s 2021 Annual General Meeting of Shareholders, to be held on July 29, 2021. Consequently, the Board and Mr. Rosebrough have determined that his status as President and CEO of the Company and STERIS Corporation (the “Employer”, and collectively with the Company, “STERIS”) and all his officerships and directorships of STERIS subsidiaries will terminate as of the same date. Mr. Rosebrough has served as President and CEO and a Director of STERIS since 2007. Mr. Rosebrough and STERIS have executed a Transition Agreement, effective July 31, 2021 (the “Agreement”). The Agreement provides for a continuation of Mr.

    Read the 8-K filing
11. Aug 3, 2020

    The Company’s Board of Directors increased the number of Directors currently serving from eight to nine members on July 28, 2020, and appointed Christopher Holland to serve as Director effective as of that date. Mr. Holland most recently served as Senior Vice President and Chief Financial Officer at C.R. Bard prior to its 2017 acquisition by Becton, Dickinson and Company. Previously Mr. Holland served as Senior Vice President of Finance and Treasurer at Aramark, and spent fifteen years at JPMorgan Chase & Co., ultimately in the role of Vice President and Medical Device Sector Head, Investment Banking. Mr. Holland also serves on the Board of Jabil Inc. and is a member of its Audit and Cybersecurity Committees. Mr. Holland will serve on the Audit and the Compensation and Organization Development Committees of the Company’s Board. Mr.

    Read the 8-K filing
12. Mar 28, 2019

    of this Current Report on Form 8-K are incorporated by reference into this

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.